Category Archives: Biotechnology

In terms of pure biotechnology, Europe has embraced innovation. However, it cannot compete with the US yet because it cannot drive private investment in the field, as well as open up the market to new products, a pharmaceutical executive told EURACTIV.com in Lyon. Despite the EUs consistent growth in the biotech business, the EBE claims that the industry is not receiving enough support from investors, universities or research institutions, thus limiting the EUs ability to keep pace with the US in biotechnology. The EU is lagging behind due to challenges in translating scientific innovations into successful businesses, a European Biopharmaceutical Enterprises (EBE) report claims. Biotechnology is the use of living systems or organisms in the creation of industrial products. The growth of the biotechnology industry is important for Europe and created 10,000 new jobs and 93 medicines recommended for market authorisation by the European Medical Agency in 2015, according to the EBE. Biotechnology could help patients across Europe gain access to innovative therapies, for example, against rare diseases. Proponents of bio-medicines also claim that precision therapy, because it is more efficient, will ease the burden on member states ailing healthcare systems. The EBE suggests that steps should be taken to … Continue reading →

Iran has made a considerable breakthrough in biotechnology inasmuch as it is able to produce GM foods and Up until 2013 it has produced 18 different kinds of recombinant medicines. The modern biotechnology has been established nearly nine decades ago in Iran, started with vaccine production in Pasteur and Razi Institutes in 1920 and 1925. National Institute of Genetic Engineering and Biotechnology institute of Iran was established in 1989. Iranian scientists are active in various spheres of agriculture in this institute and work on medicinal plants with the aim of using their metabolites or increasing their tolerance to non-biological changes such as salinity or drought. One of the uses of biotechnology is in production of genetically modified foods; however, there are many opposing voices claiming that they are harmful for health. Simply said, biotechnology harnesses cellular and bi molecular processes and puts them to work for us. It is used for production of GM foods and treating diseases with genetic technologies and many other fields. Biotechnology is an efficient, up-to-date and effective tool in agricultural field. Biotechnology helps you to improve plants' resistance to a considerable amount. Iran is among pioneering countries in this field. Up until 2013, 18 different … Continue reading →

The UF business incubator Sid Martin Biotechnology Institute was named the 2017 Top Global Incubator of the Year. The International Business Innovation Association recognized the institute March 28, said Mark Long, the institutes director. The institute received $1,500 for winning the award out of 30 other incubators. The biotechnology institute provides lab space, equipment, business and legal advice at a low cost for new biotech companies, Long said. Scientists need help understanding business and addressing the market, he said. Were here to help them out with that. The institutes 40,000 square foot facility is at Progress Park in Alachua. Its used as office and laboratory space thats rented out to new companies unable to afford commercial space. Getting an award like this is a real marketing tool in attracting new companies and investors for these companies, Long said. He said since the institute started in 1995, businesses theyve served have a 78 percent success rate, meaning 78 percent of businesses stay open after the first five years. Since 2003, the success rate has improved to 93 percent. Meekah Chaderton, a manager at the startup food development company Captozyme, said the institute helped improve the companys business. Chaderton said Captozyme plans … Continue reading →

SAN FRANCISCO--(BUSINESS WIRE)-- DevonWay, Silicon Valleys leading provider of continuous improvement software to large enterprises, announced today its expansion into a new industry with the adoption of a global, Fortune 500 biotechnology client. Biotechs emphasis on safety, quality, reliability, and innovation make it a natural fit for DevonWay software, which is in widespread use by global construction companies, utilities, and government agencies. Its an exciting time to be a part of biotech, said DevonWay CEO Chris Moustakas, and were thrilled to serve an industry that has such a huge impact on public health, disease prevention, and treatment. One of the challenges facing biotech today is maintaining a culture of innovation, which feeds the industrys rapid growth, while never sacrificing quality or safety. Were grateful for the opportunity to help the industry meet this challenge head-on. Although many biotechnology companies use Quality Management Systems to help ensure quality and regulatory compliance, those systems often lack the flexibility needed to handle specific operational requirements. Continuous improvement software, such as that provided by DevonWay, is purpose-built to bridge the gap between operations and quality, and can serve the needs of both in a single closed-loop, FDA 21CFR11-compliant system. Whether were brought on board … Continue reading →

NEW YORK, April 3, 2017 /PRNewswire/ -- Use this report to: - Explore present and future strategies within the bioseparation systems market. - Learn about the upcoming developments, the holdups and the needs of the market. - Gain an insight into acquisition strategies and collaborations by companies. Read the full report: http://www.reportlinker.com/p0619255/Separation-Systems-for-Commercial-Biotechnology.html - Receive an overview of the relevant patents related to the industry. Highlights - The global market for bioseparation reached $18.4 billion in 2015. This market is expected to increase from $19.0 billion in 2016 to nearly $24.0 billion in 2021 at a compound annual growth rate (CAGR) of 4.7% for 2016-2021. - United States market for bioseparation is expected to grow from $7.0 billion in 2016 to nearly $9.3 billion at a CAGR of 5.9% from 2016 through 2021. - Emerging market for bioseparation is expected to grow from $7.0 billion in 2016 to $8.7 billion in 2021 at a CAGR of 4.4% from 2016 through 2021. Introduction & Scope Introduction Study goals and objectives In recent years, the bioseparation systems (separation systems in biotechnology) segment has been one of growth in the biopharmaceuticals market. Primary use of these systems is for separation and purification of biological … Continue reading →

SUNNYVALE, Calif., April 3, 2017 /PRNewswire-iReach/ -- Three business and scientific leaders with early-stage investors today announced the formation of Apostle Inc, a biotechnology company developing a novel bioinformatics-enabled nanotechnology aimed for early cancer detection. This new approach will enable the early assessment of the cancerous signals in human peripheral blood plasma, which is believed to have a significant impact on the global healthcare landscape in both developed countries and emerging markets. Dr. David Dongliang Ge, an experienced business and scientific leader who was President of BioSciKin Co. and Director of Bioinformatics at Gilead Sciences, will lead the new company. He is joined by two colleagues as co-founders of Apostle and his investment partners. "Biotechnologies, especially those focusing on novel diagnostic or therapeutic advancements aiming for cancer, are among the key focuses in the global economy for the next 5-20 years. By 2020, the market size ofcancerdiagnosis is estimated to reach $168.6 billion. Apostle represents one of these focuses." Dr. Ge said. "With a groundbreaking bioinformatics-enabled nanotechnology approachwe want to inform the general population that we are able to help them identify cancer signals, earlier and more accurate than conventional techniques, and potentially advise their doctors to take highly effective … Continue reading →

April 4 Puma Biotechnology Inc: * Puma Biotechnology presents interim results of Phase II CONTROL trial of PB272 in extended adjuvant treatment of HER2-positive early stage breast cancer at the 2017 AACR annual meeting * Results of Phase II CONTROL trial showed incidence of grade 3 diarrhea for 137 patients who received loperamide prophylaxis was 30.7% * For 137 patients who received loperamide prophylaxis in Phase II CONTROL trial, 20.4% discontinued neratinib due to diarrhea * Reductions seen in incidence of severe neratinib-related diarrhea in CONTROL trial Source text for Eikon: Further company coverage: The following factors could affect Italian markets on Wednesday. * Gogo secures capacity on 12 transponders across two SES satellites Source text for Eikon: Further company coverage: (Gdynia Newsroom:) April 5 Britain's FTSE 100 index is seen opening 5 points higher on Wednesday, according to financial bookmakers, with futures up 0.3 percent ahead of the cash market open. The rest is here: BRIEF-Puma Biotechnology presents interim results of Phase II CONTROL trial of PB272 - Reuters … Continue reading →

Nasdaq Cellect Biotechnology Gets European Patent (APOP) Investopedia secured a European patent covering a method of treatment from the European Patent Office. The patent covers cell-based therapeutics of Cellect's technology and method that have the potential to treat diseases like diabetes, graft-versus-host disease, ... BRIEF-Cellect Biotechnology receives formal notice of intention to grant for a patent from European patent officeReuters UPDATE: Cellect Biotechnology (APOP) Granted European Patents ...StreetInsider.com Cellect Biotechnology Ltd. (NASDAQ:APOP) reported an European patent grantBenchmark Monitor all 9 news articles » Read the original: Cellect Biotechnology Gets European Patent (APOP) - Investopedia … Continue reading →

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that interim results from a Phase II clinical trial of Pumas investigational drug PB272 (neratinib) were presented at the 2017 American Association for Cancer Research Annual Meeting (AACR) that is currently taking place in Washington, D.C. The presentation, entitled Effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients with HER2-positive early stage breast cancer: the CONTROL trial, was presented as a poster presentation. The main adverse event that has been seen to date in clinical trials of neratinib is diarrhea and more specifically grade 3 diarrhea. In the Phase III ExteNET trial of neratinib as extended adjuvant treatment of HER2-positive early stage breast cancer that has previously been treated with adjuvant Herceptin, 95.4% of the patients experienced all grade diarrhea and 39.8% of the patients experienced grade 3 or higher diarrhea (there was one event of grade 4 diarrhea). The CONTROL trial is an international, open-label, Phase II study investigating the use of loperamide prophylaxis with or without other agents in the reduction of neratinib-associated diarrhea that has a primary endpoint of the incidence of grade 3 diarrhea. In the CONTROL trial, patients with … Continue reading →

The president of DSM Food Specialties, Ilona Haaijer, has told FoodBev that shes really excited to be able to offer laboratory and scale-up facilities as part of its new biotechnology centre in the Netherlands. The company unveiled the Rosalind Franklin Biotechnology Center on its Delft campus earlier, where more than 400 scientists will advance the companys research into food enzymes, cultures, bio-preservatives and taste ingredients for the global food industry. Alongside significant investments in robotics and automation, the centre includes space for start-ups to explore and scale up their concepts in partnership with DSM Food Specialties. At the opening: Alex Clere There was a general buzz, a sense of excitement at the unveiling of DSMs imposing glass biotechnology centre this morning. DSMs scientists had already moved in, keen to give visitors an impression of the new equipment some the result of millions of euros worth of investment and collaborative spaces in action. Ahead of the unveiling ceremony, DSM Food Specialties president Ilona Haaijer told me which of the companys products she thought were particularly pertinent, given the state of the food industry at the moment. Its MaxiLact product, which removes lactose from a product while delivering additional sugar reductions, was … Continue reading →